Antithrombin III injection via the portal vein suppresses liver damage

doi:10.3748/wjg.v18.i16.1884

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4128)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series.

Item

Count

PDF

419

HTML

3437

Figures (1-6)

272

Sum=4128

Apr 28, 2012 (publication date) through Dec 15, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Apr 28, 2012; 18(16): 1884-1891
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1884

Full Size Figure Download Figure

Figure 5 Effects of antithrombin III on serum fibrin degradation product levels. The serum fibrin degradation product (FDP) levels were determined 24 h after injection of lipopolysaccharide and D-galactosamine. Control: Untreated; TV: Antithrombin (AT) III injection via the tail vein; PV: AT III injection via the portal vein. Values are means ± SD (n = 10 rats/group). ^aP < 0.05 vs control and tail vein groups.

Citation: Miyazaki M, Kato M, Tanaka M, Tanaka K, Takao S, Kohjima M, Ito T, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R. Antithrombin III injection via the portal vein suppresses liver damage. World J Gastroenterol 2012; 18(16): 1884-1891
URL: https://www.wjgnet.com/1007-9327/full/v18/i16/1884.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i16.1884